Charles Grob

Charles Grob’s importance in the account lies in two connected roles: he helped reopen clinical research into psilocybin for people facing cancer-related anxiety, and he argued that evaluating psychedelic therapy requires taking seriously the spiritual experience and therapeutic context it involves. His work sits at the boundary between renewed medical investigation and questions that conventional drug-testing methods find difficult to contain.

Research and clinical significance

Grob, a psychiatrist at UCLA, conducted a 2011 pilot study of psilocybin for cancer anxiety. The study helped clear the path for the later NYU and Johns Hopkins trials involving patients with cancer. Those trials belonged to a renewed line of inquiry whose history had been interrupted when sanctioned psychedelic therapy ended in the 1970s. Grob described contemporary researchers as picking up work that earlier generations had been forced to set aside under cultural pressure; in his view, acceptance in modern medicine would require both recovering that buried knowledge and repeating the research to prevailing scientific standards.

The subsequent studies gave that renewed effort a significant, though still preliminary, signal. Results published together in 2016 showed clinically meaningful reductions in anxiety and depression for roughly 80 percent of the cancer patients in the two trials, with benefits persisting for at least six months. The studies were small, with eighty subjects in all, and required larger-scale replication. Their findings therefore indicate the context in which Grob’s pilot mattered: it helped make further research possible, but did not by itself establish a definitive treatment.

Psychedelic therapy as applied mysticism

Grob does not present the spiritual dimension of psychedelic treatment as something medicine can ignore. He describes the approach as “applied mysticism,” a phrase that sounds unusual within scientific practice but names a central feature of the therapy as the book portrays it: the treatment may work partly by occasioning a distinctive kind of experience, rather than through a strictly pharmacological effect alone.

That emphasis also places Grob within a debate about the role of shamanic practice in research. Franz Vollenweider regarded mysticism as an interesting shamanic concept rather than a medical one. Grob, by contrast, argued that rigorous methodology alone would not be sufficient for designing optimal studies of hallucinogens. Researchers should also attend to what successful shamanic practice can teach about arranging the conditions of an experience. In this account, the claim is not that clinical research should abandon scientific standards, but that it must examine factors those standards can otherwise leave at the edges.

Context, method, and limits

The factors Grob emphasizes include set and setting: the participant’s expectations and the environment and therapeutic relationship in which the drug is taken. Psychedelic trials are hard to blind because participants and guides can often tell whether psilocybin or a placebo was administered. It is also difficult to isolate the drug’s contribution from the guide’s presence, the session’s setting, and the volunteer’s expectations. These complications do not make research impossible, but they challenge the assumption that a drug’s effect can always be measured apart from the circumstances of its use.

Grob’s account of shamanic methods gives this challenge a practical dimension. He describes the therapist or shaman as carefully arranging the nonpharmacological conditions of treatment so that the drugs’ unusually suggestible effects can be used to therapeutic advantage. His position thus resists a simple opposition between spiritual practice and medical investigation: it asks research to study how the session is structured, not merely what compound is administered.

The book also cautions against turning promising early results into claims of a universal cure. Small studies can be shaped by volunteer selection, unusually attentive therapists, and strong expectations; reported benefits across several conditions are signals that require further testing, not proof that psychedelic therapy works for large populations. Grob’s contribution is therefore presented as both a reopening and a reframing of the clinical question: the field must test the treatment carefully while reckoning with the experience and human context that may be part of how it works.